November 2021- Global Life Science Business Partnering - News & Updates

Highlights of November 2021

    1.             Ipca Labs approves acquisition of 26.5% stake in Lyka Labs.

    2.             Wockhardt Collaborates with RDIF For Production & Supply of Covid Vaccine Sputnik-V, Sputnik Light.

    3.             Synapsica partners with GenWorks Health to promote radiology workflow solutions.

    4.             Zydus Cadila Healthcare enters into a manufacturing license and technology transfer agreement with South Korea's Enzychem for Plasmid DNA vaccine.

    5.             Nykode and Regeneron in vaccines deal worth potential US$925 Million.

    6.             Zai Lab and Blueprint Medicines sign US$600 Million deal.

    7.             Kaleo, a small drug maker and EpiPen rival, has been acquired by Marathon Asset Management in a deal valued at US$310 Million.

    8.             Sanofi inks US$270 Million cancer AI deal with R&D platform developer Owkin.

    9.             Synaffix and Mersana add license options for six ADC targets to existing deal.

    10.         Novo Nordisk to acquire Dicerna Pharmaceuticals.

    11.         Ribonexus signs license deal with Pierre Fabre in oncology.

    12.         Organon acquires Forendo Pharm.

    13.         Affibody enters agreement with Acelyrin.

    Highlights at Aagami:

    1.      Meet Aagami CEO Dinesh Jain during BIOTECH SHOWCASE 2022

    a.      January 10–12, 2022 | In-person | San Francisco, CA

    b.      January 17–19, 2022 | Virtually

    c.       Meeting calendar open. Send your meeting request soon, please.

    2.      Aagami teams up with Aleong Associates to expand footprint in China to bring added value to its global clientele.

    3.      Aagami delivered IP Audit Analysis and Valuation report to its Swedish client, in collaboration with its IP Specialist Partner Sagacious IP.

    4.      Aagami to celebrate 19th Anniversary in December 2021. Enquire for a special offer now!


    INFOCUS: Select opportunities available for Partnering:

    For Acquisition:

    1. Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package, & IP - for Next-generation biologics and substantial returns.

    For Partnering/Licensing/ Investment:

    1. US FDA approved portable MRI Guided Treatment, Diagnosis and Screening (Series C Open), limited period offer available for extended Series B.
    2. Series A - $25M Financing: Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding and licensing partnerships.
    3. Licensing, Co-development - Oncology assets such as Docetaxel, Cabazitaxel and Bendamustine, with low cost and accelerated route to market approval (From US subsidiary of a China HQ’d company).
    4. Seeking Licensing/Strategic partnerships our French client’s Phase 2 injectable drug candidate (NFL-101) for smoking cessation. It is delivered subcutaneously, twice, one week apart.
    5. Seeking $200,000 in Pre-Seed Bridge Round – Natural and Soluble Melanin (100sX lower cost) with applications in Drugs, Biomedical, cosmetics, Aerospace, energy systems to name a few. Raised $400 000 till date from Indiebio Accelerator, SOSV and other VC funds.

     

    ×
    Twitter